Drug Maker Taro Pays $205M, Enters Deferred Prosecution Pact For Antitrust Charges
PHILADELPHIA — Drug maker Taro Pharmaceuticals U.S.A. Inc. on July 23 entered into a deferred prosecution agreement (DPA) with a U.S. attorney's office for two charges of criminal antitrust activities relating...To view the full article, register now.
Already a subscriber? Click here to view full article